

OptiBiotix Health plc
("OptiBiotix" or the "Company" or the "Group")

Statement: SkinBioTherapeutics Announcement

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes provides a statement relating to the recent announcements made by SkinBioTherapeutics ("SBTX").

OptiBiotix recognises the uncertainty in the market from recent announcements by SBTX and its impact on the value of the Company's 5.64% holding in SBTX. OptiBiotix confirms it has no current intention to sell its SBTX shares. The Company confirms it has not sold any ProBiotix Health ("PBX") shares and has no current plans to sell PBX shares.

The Company's unaudited cash position as of 31st December 2025 was just over £1 million (2024: £739k) with no current requirement to raise new funds. The Company's focus is on increasing sales, improving margins, and reducing costs to develop a sustainable business, and launching its second-generation products. Considerable progress has already been made in growing sales, particularly of high margin product lines, with orders for 2026 previously reported of over £800K (announced: 21 January 2026). The Company has developed profit and loss accounts for each part of its business (OptiBiotix Health USA, OptiBiotix Health India, Ecommerce and B2B) with each business unit tasked with covering its direct costs by the end of 2026. Considerable progress has also been made in January 2026 in managing marketing spend in Ecommerce with its Amazon account now profitable and its China Ecommerce account anticipated to be profitable in forthcoming months.

Stephen O'Hara, CEO of OptiBiotix, commented:

"The board recognises the uncertainty recent announcements by SBTX have had on the value of its holding in SBTX and indirectly in OPTI itself. The Company believes the fundamentals of its business are strong and reminds investors of material progress in its SweetBiotix products (announced: 24 November 2025) and a recent large order from Meelung of 24mt (announced: 21 January 2026) and record start to 2026. The Board believes it is in the strongest position it has been in with its first-generation products and making strong progress with its second-generation products."

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Engage with the OptiBiotix management team directly by asking questions, watching video summaries and seeing what other shareholders have to say by subscribing to the new website to get regular

updates: <https://optibiotix.com/auth/signup>

View the full announcement and submit questions to management via our website: <https://optibiotix.com/link/PmpRXr>

For further information, please contact: OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Stephen O'Hara, Chief Executive

Cairn Financial Advisers LLP (NOMAD and Broker)

Tel: 020 7213 0880

Liam Murray / Ludovico Lazzaretti / James Western

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and manage human disease. Since the Group's inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC

(SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward-looking statements. Forward-looking statements are identified by their use of terms and phrases such as "believe", "could", "should", "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward-looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDUNVBRNVUUAAR